As part of the tremendous development of the animal vaccination business, which is anticipated to be worth $26.12 billion by 2030, several new research financed by both the government and the industry are being conducted to create mRNA vaccines for cattle.
Developing mRNA Vaccine
Iowa State University researchers are working on a U.S.-funded initiative. To prevent bovine respiratory syncytial virus, the Department of Agriculture is developing mRNA vaccine technology (RSV).
Animals in zoos around the nation received the mRNA COVID-19 vaccine created by the pharmaceutical company Zoetis.
And American researchers The Fish and Wildlife Service tried immunizing black-footed ferrets raised in captivity against COVID-19. They also tried social isolation and keeping ferrets in a cage.
In addition to being given to cattle, “third generation vaccinations,” such as DNA, RNA, and recombinant viral vector vaccines, are also being created for domestic pets and wild animals.
The effective use of mRNA vaccines against COVID-19 has further validated the platform and opened the floodgates to mRNA vaccine’s potential in infectious disease prevention, notably in the veterinary industry, according to a peer-reviewed study published in the journal Viruses last year.
In a five-year, multimillion-dollar agreement with the American biotech company Tiba Biotech, the New South Wales (NSW) government expedited the development of the world’s first mRNA vaccines for lumpy-skin disease and foot-and-mouth disease in September 2022, citing the need for biosecurity.
Other Reports, ’Biosecurity’
The market for animal vaccinations is predicted to expand at a compound annual growth rate of 9.3% because “more animal husbandry and the rising frequency of food-borne zoonotic illnesses are boosting the need for vaccines,” according to a research released by Grand View Research last year.
African swine fever, porcine reproductive and respiratory syndrome, porcine epidemic diarrhea, foot-and-mouth disease, bovine viral diarrhea, lumpy skin disease, bovine leukemia, and peste des petits ruminants viruses are just a few of the illnesses that could potentially be treated using the mRNA platform, according to the paper.
The Livestock Research Innovation Corporation in Ontario, Canada, recently published a white paper titled “The Future of Livestock Vaccinations” that encapsulated the change in perspective on animal vaccines.
“New technologies, such as artificial intelligence and mRNA, will significantly affect the accessibility and efficacy of vaccines available to manufacturers.”
“The present COVID-19 epidemic has taught us numerous things, including the possibility of reducing the length of time needed for vaccine research, mass manufacturing, and approval from years (or decades) to 8 to 9 months.”
An agreement between Iowa State University and Merck for the study of “emerging technologies” in animal health was established last year.
The U.S. government is supporting their collaborative research initiative to create mRNA vaccine technology to prevent bovine RSV.
The goal of the project is to create a unique, inexpensive, and thermostable mRNA platform that will “open the door for immunizing production animals with this technology.”